bromhexine has been researched along with Coronavirus Infections in 8 studies
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients had a confirmed 2019 novel coronavirus infection (COVID 19) based on a positive polymerase chain reaction (PCR) for SARS-CoV-2 virus RNA and/or a typical pattern of viral pneumonia on multispiral computed tomography." | 2.94 | [Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)]. ( Agapov, MA; Akopyan, ZA; Asratyan, DA; Begrambekova, YL; Bulanova, MM; Dyachuk, LI; Fuks, AA; Kamalov, АА; Mareev, VY; Mareev, YV; Matskeplishvili, ST; Mershina, ЕА; Orlova, YA; Pakhomov, PV; Pavlikova, EP; Plisyk, AG; Potapenko, AV; Samokhodskaya, LM; Seredenina, EM; Sinitsyn, VE, 2020) |
| " Using bromhexine at a dosage that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific viral entry is likely to be effective against SARS-CoV-2." | 2.66 | Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? ( de Villiers, D; Depfenhart, M; Di Somma, S; Lemperle, G; Meyer, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Maggio, R | 1 |
| Corsini, GU | 1 |
| Habtemariam, S | 1 |
| Nabavi, SF | 1 |
| Ghavami, S | 1 |
| Cismaru, CA | 1 |
| Berindan-Neagoe, I | 1 |
| Nabavi, SM | 1 |
| Depfenhart, M | 1 |
| de Villiers, D | 1 |
| Lemperle, G | 1 |
| Meyer, M | 1 |
| Di Somma, S | 1 |
| Nitulescu, GM | 1 |
| Paunescu, H | 1 |
| Moschos, SA | 1 |
| Petrakis, D | 1 |
| Nitulescu, G | 1 |
| Ion, GND | 1 |
| Spandidos, DA | 1 |
| Nikolouzakis, TK | 1 |
| Drakoulis, N | 1 |
| Tsatsakis, A | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Xue, K | 1 |
| Zhang, T | 1 |
| Ren, X | 1 |
| Mareev, VY | 2 |
| Orlova, YA | 2 |
| Pavlikova, EP | 2 |
| Matskeplishvili, ST | 2 |
| Akopyan, ZA | 2 |
| Plisyk, AG | 2 |
| Seredenina, EM | 2 |
| Asratyan, DA | 2 |
| Potapenko, AV | 2 |
| Malakhov, PS | 1 |
| Samokhodskaya, LM | 2 |
| Mershina, EA | 1 |
| Sinitsyn, VE | 2 |
| Bulanova, MM | 2 |
| Fuks, AA | 2 |
| Mareev, YV | 2 |
| Begrambekova, YL | 2 |
| Kamalov, AA | 1 |
| Agapov, MA | 1 |
| Dyachuk, LI | 1 |
| Mershina, ЕА | 1 |
| Pakhomov, PV | 1 |
| Kamalov, АА | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for bromhexine and Coronavirus Infections
| Article | Year |
|---|---|
Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Humans; Pandemics; Pneu | 2020 |
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Betacoronavirus; Bromhexin | 2020 |
1 trial available for bromhexine and Coronavirus Infections
| Article | Year |
|---|---|
[Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)].
Topics: Bromhexine; Coronavirus Infections; COVID-19; Hospitalization; Humans; Prospective Studies; SARS-CoV | 2020 |
5 other studies available for bromhexine and Coronavirus Infections
| Article | Year |
|---|---|
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.
Topics: Antitussive Agents; Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Hum | 2020 |
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Humans; Pandemics; Pneu | 2020 |
Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review.
Topics: Betacoronavirus; Bromhexine; Child; Coronavirus Infections; COVID-19; Expectorants; Humans; Meta-Ana | 2020 |
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)"].
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalizat | 2020 |